Real-world Effectiveness and Safety of Treatment With DAAs in Patients With CHC(Chronic Hepatitis C)

Inclusion Criteria: * Male and female subjects with age \>18 years old. * HCV RNA ≥1×103IU/mL * Genotype 1-6 HCV infection. * Confirmed CHC defined as: (1)Confirmed HCV infection more than 6 months at baseline, including anti-HCV positive or HCV RNA positive for at least 6 months; (2)Confirmed HCV infection by liver biopsy one year before baseline. * Negative pregnancy test for females of childbearing potential (18 years old to one year after menopause) at screening. * Males and females of childbearing potential should agree to take mechanic contraceptives from screening to at least 6 months after discontinuation of treatment. * Informed of, willing and able to comply with all of the protocol requirements and the investigational nature of the study. * A signed written informed consent from patient. Exclusion Criteria: * History of clinically significant medical condition associated with other chronic liver disease (including hemochromatosis, autoimmune hepatitis, Wilson's disease, α1-antitrypsin deficiency, alcoholic liver disease, drug-induced liver injury). * Stomach disorder that could interfere with the absorption of the study drug. * Serious or active medical or psychiatric illness. If the participant has received more than 12 months of treatment and the condition is stable, or the participant does not need any medicine during the previous 12 months, the participant is allowed to enrollment. * Uncontrolled serious cardiovascular disease (such as ventricular tachyarrhy…